Cargando…
Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease
Biomarkers have the potential to aid in the study of Alzheimer’s disease (AD); unfortunately, AD biomarker values often have a high degree of overlap between healthy and AD individuals. This study investigates the potential utility of a series of novel AD biomarkers, the sixty second (129)Xe retenti...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023430/ https://www.ncbi.nlm.nih.gov/pubmed/29882765 http://dx.doi.org/10.3390/diagnostics8020041 |
_version_ | 1783335867098595328 |
---|---|
author | Hane, Francis T. Li, Tao Plata, Jennifer-Anne Hassan, Ayman Granberg, Karl Albert, Mitchell S. |
author_facet | Hane, Francis T. Li, Tao Plata, Jennifer-Anne Hassan, Ayman Granberg, Karl Albert, Mitchell S. |
author_sort | Hane, Francis T. |
collection | PubMed |
description | Biomarkers have the potential to aid in the study of Alzheimer’s disease (AD); unfortunately, AD biomarker values often have a high degree of overlap between healthy and AD individuals. This study investigates the potential utility of a series of novel AD biomarkers, the sixty second (129)Xe retention time, and the xenon washout parameter, based on the washout of hyperpolarized (129)Xe from the brain of AD participants following inhalation. The xenon washout parameter is influenced by cerebral perfusion, T1 relaxation of xenon, and the xenon partition coefficient, all factors influenced by AD. Participants with AD (n = 4) and healthy volunteers (n = 4) were imaged using hyperpolarized (129)Xe magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) to determine the amount of retained xenon in the brain. At 60 s after the breath hold, AD patients retained significantly higher amounts of (129)Xe compared to healthy controls. Data was fit to a pharmacokinetic model and the xenon washout parameter was extracted. Xenon washout in white and grey matter occurs at a slower rate in Alzheimer’s participants ((129)Xe half-life time of 42 s and 43 s, respectively) relative to controls (20 s and 16 s, respectively). Following larger scale clinical trials for validation, the xenon washout parameter has the potential to become a useful biomarker for the support of AD diagnosis. |
format | Online Article Text |
id | pubmed-6023430 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60234302018-07-13 Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease Hane, Francis T. Li, Tao Plata, Jennifer-Anne Hassan, Ayman Granberg, Karl Albert, Mitchell S. Diagnostics (Basel) Article Biomarkers have the potential to aid in the study of Alzheimer’s disease (AD); unfortunately, AD biomarker values often have a high degree of overlap between healthy and AD individuals. This study investigates the potential utility of a series of novel AD biomarkers, the sixty second (129)Xe retention time, and the xenon washout parameter, based on the washout of hyperpolarized (129)Xe from the brain of AD participants following inhalation. The xenon washout parameter is influenced by cerebral perfusion, T1 relaxation of xenon, and the xenon partition coefficient, all factors influenced by AD. Participants with AD (n = 4) and healthy volunteers (n = 4) were imaged using hyperpolarized (129)Xe magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) to determine the amount of retained xenon in the brain. At 60 s after the breath hold, AD patients retained significantly higher amounts of (129)Xe compared to healthy controls. Data was fit to a pharmacokinetic model and the xenon washout parameter was extracted. Xenon washout in white and grey matter occurs at a slower rate in Alzheimer’s participants ((129)Xe half-life time of 42 s and 43 s, respectively) relative to controls (20 s and 16 s, respectively). Following larger scale clinical trials for validation, the xenon washout parameter has the potential to become a useful biomarker for the support of AD diagnosis. MDPI 2018-06-06 /pmc/articles/PMC6023430/ /pubmed/29882765 http://dx.doi.org/10.3390/diagnostics8020041 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Hane, Francis T. Li, Tao Plata, Jennifer-Anne Hassan, Ayman Granberg, Karl Albert, Mitchell S. Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease |
title | Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease |
title_full | Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease |
title_fullStr | Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease |
title_full_unstemmed | Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease |
title_short | Inhaled Xenon Washout as a Biomarker of Alzheimer’s Disease |
title_sort | inhaled xenon washout as a biomarker of alzheimer’s disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6023430/ https://www.ncbi.nlm.nih.gov/pubmed/29882765 http://dx.doi.org/10.3390/diagnostics8020041 |
work_keys_str_mv | AT hanefrancist inhaledxenonwashoutasabiomarkerofalzheimersdisease AT litao inhaledxenonwashoutasabiomarkerofalzheimersdisease AT platajenniferanne inhaledxenonwashoutasabiomarkerofalzheimersdisease AT hassanayman inhaledxenonwashoutasabiomarkerofalzheimersdisease AT granbergkarl inhaledxenonwashoutasabiomarkerofalzheimersdisease AT albertmitchells inhaledxenonwashoutasabiomarkerofalzheimersdisease |